ERBB2 and neoplasm: As the measurement of the expression of the HER-2 gene itself was chosen as important contributing factor in this ‘knowledge-driven approach’, most if not all HER-2-positive tumours are classified as intermediate or high risk and therefore, this assay is unlikely to add prognostic information for HER-2-positive disease.